Literature DB >> 24619620

Bacteriophages as potential treatment option for antibiotic resistant bacteria.

Robert Bragg1, Wouter van der Westhuizen, Ji-Yun Lee, Elke Coetsee, Charlotte Boucher.   

Abstract

The world is facing an ever-increasing problem with antibiotic resistant bacteria and we are rapidly heading for a post-antibiotic era. There is an urgent need to investigate alterative treatment options while there are still a few antibiotics left. Bacteriophages are viruses that specifically target bacteria. Before the development of antibiotics, some efforts were made to use bacteriophages as a treatment option, but most of this research stopped soon after the discovery of antibiotics. There are two different replication options which bacteriophages employ. These are the lytic and lysogenic life cycles. Both these life cycles have potential as treatment options. There are various advantages and disadvantages to the use of bacteriophages as treatment options. The main advantage is the specificity of bacteriophages and treatments can be designed to specifically target pathogenic bacteria while not negatively affecting the normal microbiota. There are various advantages to this. However, the high level of specificity also creates potential problems, the main being the requirement of highly specific diagnostic procedures. Another potential problem with phage therapy includes the development of immunity and limitations with the registration of phage therapy options. The latter is driving research toward the expression of phage genes which break the bacterial cell wall, which could then be used as a treatment option. Various aspects of phage therapy have been investigated in studies undertaken by our research group. We have investigated specificity of phages to various avian pathogenic E. coli isolates. Furthermore, the exciting NanoSAM technology has been employed to investigate bacteriophage replication and aspects of this will be discussed.

Entities:  

Mesh:

Year:  2014        PMID: 24619620     DOI: 10.1007/978-81-322-1777-0_7

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  13 in total

Review 1.  Antimicrobial bacteriophage-derived proteins and therapeutic applications.

Authors:  Dwayne R Roach; David M Donovan
Journal:  Bacteriophage       Date:  2015-06-23

2.  Structure-Activity Relationship of Peptide-Conjugated Chloramphenicol for Inhibiting Escherichia coli.

Authors:  Jiaqing Wang; Adrianna Shy; Difei Wu; Deani L Cooper; Jiashu Xu; Hongjian He; Wenjun Zhan; Shenghuan Sun; Susan T Lovett; Bing Xu
Journal:  J Med Chem       Date:  2019-11-12       Impact factor: 7.446

3.  Expansion of Bacteriophages Is Linked to Aggravated Intestinal Inflammation and Colitis.

Authors:  Lasha Gogokhia; Kate Buhrke; Rickesha Bell; Brenden Hoffman; D Garrett Brown; Christin Hanke-Gogokhia; Nadim J Ajami; Matthew C Wong; Arevik Ghazaryan; John F Valentine; Nathan Porter; Eric Martens; Ryan O'Connell; Vinita Jacob; Ellen Scherl; Carl Crawford; W Zac Stephens; Sherwood R Casjens; Randy S Longman; June L Round
Journal:  Cell Host Microbe       Date:  2019-02-13       Impact factor: 21.023

Review 4.  Novel therapeutic interventions towards improved management of septic arthritis.

Authors:  Jian Wang; Liucai Wang
Journal:  BMC Musculoskelet Disord       Date:  2021-06-09       Impact factor: 2.362

Review 5.  The global threat of antimicrobial resistance: science for intervention.

Authors:  I Roca; M Akova; F Baquero; J Carlet; M Cavaleri; S Coenen; J Cohen; D Findlay; I Gyssens; O E Heuer; G Kahlmeter; H Kruse; R Laxminarayan; E Liébana; L López-Cerero; A MacGowan; M Martins; J Rodríguez-Baño; J-M Rolain; C Segovia; B Sigauque; E Tacconelli; E Wellington; J Vila
Journal:  New Microbes New Infect       Date:  2015-04-16

6.  Biocide Selective TolC-Independent Efflux Pumps in Enterobacteriaceae.

Authors:  Carmine J Slipski; George G Zhanel; Denice C Bay
Journal:  J Membr Biol       Date:  2017-10-23       Impact factor: 1.843

Review 7.  Drug Resistance and the Prevention Strategies in Food Borne Bacteria: An Update Review.

Authors:  Fataneh Hashempour-Baltork; Hedayat Hosseini; Saeedeh Shojaee-Aliabadi; Mohammadali Torbati; Adel Mirza Alizadeh; Matin Alizadeh
Journal:  Adv Pharm Bull       Date:  2019-08-01

8.  Development of a qPCR platform for quantification of the five bacteriophages within bacteriophage cocktail 2 (BFC2).

Authors:  Hans Duyvejonck; Maya Merabishvili; Jean-Paul Pirnay; Daniel De Vos; Gilbert Verbeken; Jonas Van Belleghem; Tessa Gryp; Julie De Leenheer; Kelly Van der Borght; Leen Van Simaey; Stefan Vermeulen; Els Van Mechelen; Mario Vaneechoutte
Journal:  Sci Rep       Date:  2019-09-25       Impact factor: 4.379

9.  Antibacterial Activity of Stenotrophomonas maltophilia Endolysin P28 against both Gram-positive and Gram-negative Bacteria.

Authors:  Hongling Dong; Chaoyang Zhu; Jingyi Chen; Xing Ye; Yu-Ping Huang
Journal:  Front Microbiol       Date:  2015-11-24       Impact factor: 5.640

10.  Formation of therapeutic phage cocktail and endolysin to highly multi-drug resistant Acinetobacter baumannii: in vitro and in vivo study.

Authors:  Hayder Nsaif Jasim; Rand Riadh Hafidh; Ahmed Sahib Abdulamir
Journal:  Iran J Basic Med Sci       Date:  2018-11       Impact factor: 2.699

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.